Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Long-Term Investments (2016 - 2025)

Voyager Therapeutics' Long-Term Investments history spans 11 years, with the latest figure at $5.2 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 92.02% year-over-year to $5.2 million; the TTM value through Dec 2025 reached $5.2 million, down 92.02%, while the annual FY2025 figure was $5.2 million, 92.02% down from the prior year.
  • Long-Term Investments for Q4 2025 was $5.2 million at Voyager Therapeutics, down from $20.1 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $65.7 million in Q4 2024 and bottomed at $1.5 million in Q2 2022.
  • The 5-year median for Long-Term Investments is $2.0 million (2021), against an average of $11.3 million.
  • The largest annual shift saw Long-Term Investments soared 4024.54% in 2024 before it tumbled 92.02% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $1.8 million in 2021, then decreased by 14.84% to $1.5 million in 2022, then grew by 5.15% to $1.6 million in 2023, then skyrocketed by 4024.54% to $65.7 million in 2024, then crashed by 92.02% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Long-Term Investments are $5.2 million (Q4 2025), $20.1 million (Q3 2025), and $46.4 million (Q2 2025).